Paxlovid

One in five people who take nirmatrelvir/ritonavir (Paxlovid) get COVID-19 again after the drug clears them of it, according to a new study.

Paxlovid didn’t help older adults with long COVID, study shows … What geriatricians should know about monoclonal anti-amyloid antibodies for Alzheimer’s … High salt linked to type 2 diabetes...

Even though it may be more pricey for some people to get Paxlovid soon, a new study finds that taking it is linked to a small reduction in long COVID. The same is true for Lagevrio, the other oral drug...

Adults who took Paxlovid when they had COVID-19 had a high prevalence of interactions with other drugs, according to a new study. For the most part, the effects of the interactions weren’t too serious...

Paxlovid, an oral drug that treats COVID-19, is set to hit the commercial market next month after being managed by the United States federal government since its release. On Wednesday, Pfizer announced...

Paxlovid, an oral drug that treats COVID-19, will begin to enter the commercial market starting next month. At the same time, the US federal government is making sure that the country has enough supply,...

As news that COVID-19 activity has declined emerged Monday, a new study was released showing that people vulnerable to severe COVID-19 who took nirmatrelvir and ritonavir (Paxlovid) had a lower risk for...

People with COVID-19 at risk for severe disease had a lower risk for death and hospitalization if they took nirmatrelvir (Paxlovid) or balapiravir (Lagevrio) compared to no treatment at all, a new study...

Paxlovid, which received emergency use authorization in December of 2021, continues to be an effective treatment for COVID-19, the agency said Thursday.

SARS-CoV-2 variants already are showing mutations that may make them resistant to the COVID-19 pill Paxlovid and at least one other approved antiviral drug, researchers report.